^
    21h
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    21h
    Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (clinicaltrials.gov)
    P=N/A, N=27, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • Duoenda (mitoxantrone liposomal)
    22h
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    22h
    MCC-20963: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (clinicaltrials.gov)
    P2, N=25, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Inrebic (fedratinib)
    22h
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    23h
    GRANS: Granulocyte Transfusions After Umbilical Cord Blood Transplant (clinicaltrials.gov)
    P=N/A, N=40, Active, not recruiting, University of Manchester | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    23h
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    23h
    Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation. (PubMed, J Med Chem)
    Moreover, Compound 14 demonstrated an impressive pharmacokinetic profile and exerted significant antitumor efficacy in the FLT3-ITD-positive AML xenograft mouse model (approximately 80% decrease in tumor mass). Also, biochemical blood analysis and histopathological studies revealed that Compound 14 demonstrated a good safety profile.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • SYK (Spleen tyrosine kinase)
    |
    FLT3-ITD mutation
    24h
    TMF-Allo: Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=150, Recruiting, University Hospital, Clermont-Ferrand | Trial completion date: Dec 2027 --> May 2030 | Trial primary completion date: Oct 2026 --> May 2030
    Trial completion date • Trial primary completion date
    24h
    MRD Detection by NGS in Pediatric T-ALL (clinicaltrials.gov)
    P=N/A, N=148, Completed, The Children's Hospital of Zhejiang University School of Medicine | N=69 --> 148 | Trial completion date: Dec 2022 --> Dec 2025
    Enrollment change • Trial completion date • IO biomarker
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    1d
    PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)